With this step, Biogénesis Bagó enters the top 10 animal health companies for pets in Latin America and incorporates new products that will reach a global portfolio of more than 200 solutions for this segment.   

São Paulo, January 16th, 2025.- Biogénesis Bagó, a global biotechnology company specialized in the development, production and commercialization of products and services for animal health, productivity and welfare, announced the acquisition of Mundo Animal, a company with more than 40 years of experience in the Brazilian pet market.

This milestone strengthens the global expansion obtained in recent years that allows the Argentinean company to now have 12 offices and 7 production plants from which it supplies animal health solutions to more than 60 countries in the world.

"The integration of Mundo Animal expands our portfolio and is an opportunity to continue creating new possibilities together. Their history in the Brazilian market and their passion for providing quality products are aligned with our commitment to contribute to improving the well-being of our life partners," said Carol Galli, veterinarian and director of the Pets segment of Biogénesis Bagó.

Mundo Animal has a manufacturing and R+D site in Pindamonhangaba, São Paulo state, Brazil, where they develop and manufacture solutions for nutrition, medicine and hygiene for pets. The products produced there will complement Biogénesis Bagó's creating a global portfolio of more than 200 solutions for this segment.

"As part of our strategy of diversification in territories and species, at Biogénesis Bagó we have been committed to continued growth in the pet segment. The acquisition of Mundo Animal, in addition to the decisions made in recent years, are key steps in fulfilling our strategic plan to be part of the Top 20 companies in the global veterinary market”, said Esteban Turic, CEO of Biogénesis Bagó.

Brazil is the third largest market in the world for pets. The acquisition come after the tech transfer agreement that Biogénesis Bagó signed with the Paraná Institute of Technology (TECPAR) to produce rabies vaccines in Brazil and the recent acquisition of Campo Largo, a manufacturing site located in Curitiba. where it will produce more than 10 million doses of vaccines for pets. The sum of these milestones positions Biogénesis Bagó as the largest producer of veterinary vaccines in Latin America.

Through this incorporation, Biogénesis Bagó strengthens its position as an increasingly important player in the global veterinary market, with a growing portfolio, reinforcing its commitment to veterinarians and pet owners through the offer of comprehensive solutions to improve the health, well-being and longevity of pets.